# Big Pharma Shorthand for the large pharmaceutical and biotech industry as a political-economic bloc. The term carries a double life that makes it unusually important for this KB: it names a *real* power structure — the most consistently dominant [[Lobbying]] force in Washington — and it simultaneously functions as a *conspiracy floating signifier* on both the populist left and the [[MAHA]] right. Understanding which register a speaker is using is half the analysis. ## The Real Power Structure The pharmaceutical and health-products sector routinely tops all industries in federal lobbying. It spent roughly **$388 million on federal lobbying in 2024**, with [[PhRMA]] (the industry's main trade association) alone spending about $31 million in 2024 and $37.9 million in 2025 — record-breaking totals in consecutive years, deployed against Medicare negotiation expansion and pricing transparency — and *for* shifting blame onto [[Pharmacy Benefit Managers]], the deflection campaign that ultimately delivered the February 2026 PBM reform law while leaving manufacturer pricing untouched. The structural mechanisms are the classic ones documented across this vault: - **[[Revolving Door]]** — executives and regulators cycling between industry and the agencies that oversee it. [[Alex Azar]] (Lilly USA president → HHS Secretary) is the canonical case; [[Scott Gottlieb]] ([[FDA]] Commissioner → [[Pfizer]] board) is another. - **[[Regulatory Capture]]** — the [[FDA]]'s user-fee funding model (industry fees fund a large share of the drug-review budget), industry-friendly advisory panels, and accelerated-approval pathways. - **Protected pricing** — Medicare Part D was written in 2003 to *prohibit* the government from negotiating drug prices, a prohibition that held until the [[Inflation Reduction Act]] cracked it open in 2022. - **[[Dark Money]] and patient-group astroturf** — industry funding flowing through ostensibly independent patient-advocacy organizations that lobby against price controls. ## Case Studies in This Vault **The opioid crisis** is the most fully documented example of pharma power operating as a corporate-crime machine: [[Purdue Pharma]] and the [[Sackler Family]] (with international arms [[Mundipharma]] and [[Rhodes Pharmaceuticals]]) marketed OxyContin through captured regulators, funded pain-treatment front groups, and litigated their way to a liability shield the Supreme Court struck down in [[Harrington v. Purdue Pharma]]. Full chronology at [[Opioid Crisis Timeline]]. **The insulin cartel** — [[Eli Lilly]], [[Novo Nordisk]], and [[Sanofi]] raised U.S. insulin list prices in near-lockstep for two decades (Lilly's Humalog roughly doubled from 2012 to 2017, under Azar's leadership of Lilly USA). Pressure from the IRA's $35 Medicare insulin cap and looming litigation pushed all three to announce dramatic list-price cuts in 2023. **COVID-19** — [[Operation Warp Speed]] showcased the industry's capacity when de-risked with public money, and simultaneously seeded the deepest well of anti-pharma populism the right has ever had. See [[COVID-19 Timeline]] and [[COVID Response Politicization]]. ## The Right-Wing Realignment Historically, hostility to drug companies lived on the left (Medicare negotiation, importation, price caps) while the GOP defended the industry's IP and pricing freedom. Two things scrambled that map: 1. **COVID vaccine politics.** The [[Anti-Vax Movement]] migrated rightward and fused with general anti-institutional distrust, making "Big Pharma" a stock villain in right-wing media — see [[COVID Lab Leak Weaponization]] for the adjacent narrative machinery. 2. **[[MAHA]].** [[Robert F. Kennedy Jr]] — built by [[Children's Health Defense]] and elevated to HHS Secretary — along with operatives like [[Calley Means]] and [[Casey Means]], turned anti-pharma populism into governing ideology. The result is incoherent in revealing ways: a Republican administration attacking mRNA research funding while [[Donald Trump]] simultaneously claims credit for Operation Warp Speed and cuts most-favored-nation pricing deals (the September 2025 [[Pfizer]] deal, the November 2025 GLP-1 deals with Lilly and [[Novo Nordisk]], and the TrumpRx platform — see [[Most-Favored-Nation Drug Pricing Deals]]) that the industry's lobbyists shaped. The analytical point: right-wing anti-pharma politics attacks the industry's *products* (vaccines, GLP-1s, SSRIs) far more than its *power* (pricing, patents, lobbying). MAHA rhetoric and industry lobbying coexist comfortably — the lobbying record budgets of 2024–25 came *during* the MAHA ascendancy. ## Watch For - Whether Medicare negotiation (IRA) survives industry litigation and the current administration's selective enforcement - The [[Most-Favored-Nation Drug Pricing Deals]] as a template: price theater negotiated bilaterally with presidential branding, in place of structural reform - [[Guardant Health]]-style diagnostics plays — Medicare-coverage rulemaking as the new high-margin frontier, with the same revolving-door personnel ([[Alex Azar]]) ## Connections - [[Alex Azar]] — The revolving door personified; Lilly → HHS → Guardant - [[Sackler Family]] / [[Purdue Pharma]] — Corporate-crime case study; see [[Opioid Crisis Timeline]] - [[Eli Lilly]] — Insulin cartel member turned first $1T healthcare company - [[MAHA]] / [[Robert F. Kennedy Jr]] — Right-populist anti-pharma ideology in power - [[Regulatory Capture]], [[Revolving Door]], [[Lobbying]], [[Dark Money]] — The mechanism pages - [[Inflation Reduction Act]] / [[Affordable Care Act]] — The legislative battlefield